N🟁N

Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2010 Financial Results on November 1, 2010

  //health-fitness.news-articles.net/content/2010/ .. r-2010-financial-results-on-november-1-2010.html
  Published in Health and Fitness on Tuesday, October 19th 2010 at 6:10 GMT by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

BOTHELL, Wash.--([ BUSINESS WIRE ])--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its third quarter 2010 financial results on Monday, November 1, 2010, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

LIVE access on Monday, November 1, 2010

2:00 p.m. Pacific Time (PT) / 5:00 p.m. Eastern Time (ET)

• Telephone (877) 941-8632 (domestic) or (480) 629-9820 (international); conference ID 4373835
• Webcast available at [ http://www.seattlegenetics.com ] in the Investors and News section

REPLAY access

• Telephone replay will be available beginning at approximately 4:00 p.m. PT on November 1, 2010 through 4:00 p.m. PT on November 3, 2010 by calling (800) 406-7325 (domestic) or (303) 590-3030 (international); conference ID 4373835
• Webcast replay will be available on the Seattle Genetics website at [ http://www.seattlegenetics.com ] in the Investors and News section

About Seattle Genetics

Seattle Genetics is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company recently reported positive top-line data from both a pivotal Hodgkin lymphoma trial and phase II anaplastic large cell lymphoma trial with its lead product candidate, brentuximab vedotin, and plans to submit a Biologics License Application to the U.S. Food and Drug Administration in the first half of 2011. Brentuximab vedotin is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has four other clinical-stage programs: SGN-75, ASG-5ME, dacetuzumab (SGN-40) and SGN-70. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium: The Takeda Oncology Company and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at [ www.seattlegenetics.com ].